Introduction

Cardiac amyloidosis (CA) is an underdiagnosed cause of heart failure in Africa. This survey, coordinated by the Kenya Cardiac Society (KCS) in collaboration with CRK Clinical Research Key (NGO) and partners, aims to better understand the current awareness, diagnostic capacity, and management practices of CA among healthcare providers. The study is part of the KCS Registry Program on Cardiac Amyloidosis Screening and Implementation Science in Kenya, and its findings will guide future national and regional initiatives.

Purpose

The goal of this survey is to collect information on:

• Healthcare professionals’ experience diagnosing and managing cardiac amyloidosis.
• Availability and use of diagnostic modalities such as echocardiography, cardiac MRI, 99mTc-PYP scintigraphy, and genetic testing.
• Access to disease-modifying therapies (DMTs) and local referral pathways.

Results will inform the upcoming PREDICT-AMY Kenya Study, which will evaluate AI-powered ECG screening for cardiac amyloidosis in low-resource settings.

Duration

The survey will take approximately 10-12 minutes to complete and will remain open for eight weeks.
Participation is voluntary, and you may choose to withdraw at any time before submission.

PREDICT-AMY Kenya Study Duration

18 months

Confidentiality

Your responses will remain strictly anonymous. No identifying personal data will be collected. All data will be stored securely and analyzed only in aggregate form by the CRK Clinical Research Key (NGO) Data Management and Biostatistics Team in accordance with Good Clinical Data Management Practices (GCDMP).
Findings will be used solely for scientific and educational purposes and may be published with proper acknowledgment to the Kenya Cardiac Society Registry.